IMAC (NASDAQ:IMAC – Get Rating) had its target price reduced by Ascendiant Capital Markets to $5.50 in a research report report published on Monday, Stock Target Advisor reports. Ascendiant Capital Markets currently has a na rating on the stock.
NASDAQ:IMAC opened at $0.81 on Monday. IMAC has a 52 week low of $0.75 and a 52 week high of $2.75. The stock’s fifty day moving average is $0.91 and its two-hundred day moving average is $1.12. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.27 and a current ratio of 1.27.
IMAC (NASDAQ:IMAC – Get Rating) last announced its earnings results on Friday, May 13th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). IMAC had a negative net margin of 75.40% and a negative return on equity of 52.17%. Equities research analysts predict that IMAC will post -0.62 EPS for the current fiscal year.
About IMAC (Get Rating)
IMAC Holdings, Inc owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains.
- Get a free copy of the StockNews.com research report on IMAC (IMAC)
- Etsy Buy!: Why Etsy Stock is Making a Crafty Comeback
- FIGS, Inc Moves Lower On Analysts’ Downgrades
- Option Care Health Stock is Making a Healthy Pullback
- MarketBeat Podcast: Trading Volatile Markets While Preserving Capital
- Warby Parker Stock Is A High-Probability Candidate For A Short-Squeeze
Receive News & Ratings for IMAC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMAC and related companies with MarketBeat.com's FREE daily email newsletter.